WuXi Biologics has secured a major regulatory win in Europe, with its Suzhou Biosafety Testing Center passing its fourth Good Manufacturing Practice (GMP) inspection from the European Medicines Agency (EMA) with zero critical findings.

 

The latest clearance reinforces the site’s role as a key global quality hub for biologics testing and directly supports European Union marketing authorization applications covering 19 biologic products from 13 clients. These programs—largely developed and manufactured on WuXi Biologics’ integrated platform—span antibodies, enzymes, and fusion proteins.

 

The EMA inspection focused on biosafety quality control testing for cell banks and commercial unprocessed bulk materials tied to these products. Over four days, inspectors evaluated quality management systems, facilities and equipment, testing methodologies, standard operating procedures, computerized systems, and personnel competency. 

 

The agency reportedly recognized the site’s quality systems, infrastructure, technical capabilities, data integrity, and organizational management.

 

GMP-compliant biosafety testing is a critical regulatory requirement for biologics entering the European market, forming a core part of both pre-license inspections and ongoing commercial product oversight.

 

Chris Chen, CEO of WuXi Biologics, commented: "From preliminary safety validation at cell bank and harvest stages to final quality control at commercial batch release, biosafety testing spans critical stages across the entire lifecycle of biologics, ensuring compliance with rigorous regulatory requirements from development through commercialization. 

 

"We remain committed to maintaining a high-quality system aligned with global GMP standards as a cornerstone to ensure product quality. This capability is consistently demonstrated and implemented across our global network, reflecting our long-standing commitment to enabling our partners and ultimately benefiting patients worldwide."

 

The Suzhou Biosafety Testing Center—together with its Shanghai facility—provides end-to-end biosafety services, including cell bank characterization for CHO, HEK293, and E. coli systems, GMP release testing, and GLP-compliant viral clearance studies supported by in-house virus production capabilities. As of December 2025, the network has supported more than 1,700 IND or BLA applications.

 

Beyond the EMA, the center has accumulated a broad record of global regulatory recognition, including FDA interactive evaluation and successful inspections by authorities such as CNAS, NMPA, Health Canada, TGA, and PMDA, along with more than 510 client quality audits.

 

The latest EMA certification further strengthens WuXi Biologics’ position as a major enabler of global biologics development and commercialization—particularly for products advancing toward or already in commercial supply for the European market.